middle.news
How Imugene’s Azer-cel Is Reshaping Blood Cancer Treatment with FDA Fast Track
11:24pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
How Imugene’s Azer-cel Is Reshaping Blood Cancer Treatment with FDA Fast Track
11:24pm on Friday 29th of August, 2025 AEST
Key Points
54% reduction in net loss to $69 million for FY25
Azer-cel shows 79% overall response rate in Phase 1b trial
FDA grants Fast Track designation to azer-cel
Raised approximately $42 million through funding rounds
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE